Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover access and long-term safety study of berotralstat in hereditary angioedema
MOH_2025-12-28_015566Phase 3Recruiting
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Long-term safety, Serious adverse events and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2025-12-28_015566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-28_015566.